ArticleCureus2026
Ischemic Stroke in a Young Adult Male During Finasteride Therapy.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Finasteride, a 5-alpha-reductase inhibitor widely prescribed for androgenetic alopecia, is generally considered safe, with most reported adverse effects being sexual or neuropsychiatric in nature. However, recent literature data have raised concerns regarding rare thrombotic complications. The mechanistic basis and clinical relevance of this association remain unclear, particularly in young individuals without traditional risk factors. We report a case of ischemic stroke with left internal carotid artery multilevel stenosis and capsulo-thalamic infarction in a 20-year-old previously healthy male taking finasteride 1 mg daily for androgenetic alopecia. Comprehensive evaluation revealed heterozygous Factor V Leiden mutation, MTHFR compound heterozygosity, PAI-1 4G allele carriage, and ACE D allele polymorphism. Cardioembolic evaluation was unremarkable, and autoimmune testing was negative. Finasteride was discontinued, and the patient was treated with antiplatelet therapy and rehabilitation, with partial neurological recovery. This case highlights ischemic stroke occurring in the setting of a likely intracranial steno-occlusive arteriopathy, with concurrent finasteride exposure as a possible compounding factor. While causality cannot be definitively established, clinicians should remain vigilant when prescribing finasteride to individuals with prothrombotic predispositions. Further observational studies are needed to clarify absolute risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.